Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Human Leukocyte Antigen

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    71 result(s) found for: Human Leukocyte Antigen. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2017-002241-30 Sponsor Protocol Number: CEC-3/CEL Start Date*: 2018-01-30
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: A phase IIa, double-blind, randomised, placebo-controlled, dose-finding study on the efficacy and tolerability of a 6-week treatment with ZED1227 capsules vs. placebo in subjects with well-controll...
    Medical condition: Treatment of celiac disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10007864 Celiac disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) FI (Completed) DE (Completed) AT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001656-41 Sponsor Protocol Number: TCeD21 Start Date*: 2022-12-07
    Sponsor Name:Topas Therapeutics GmbH
    Full Title: A double-blind, randomized, placebo-controlled, phase 2a study to evaluate the safety, tolerability, and pharmacodynamic (PD) effects of two infusions of escalating doses of TPM502 in adults diagno...
    Medical condition: Coeliac disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing) FI (Ongoing) DE (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004862-24 Sponsor Protocol Number: ESBA105CRD04 Start Date*: 2009-01-02
    Sponsor Name:ESBATech, an Alcon Biomedical Research Unit LLC
    Full Title: An open-label exploratory study to assess the safety, tolerability and clinical activity of topically applied ESBA105 in patients with acute anterior uveitis
    Medical condition: Acute, unilateral anterior uveitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002709 Anterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000322-66 Sponsor Protocol Number: CRAD001A2433 Start Date*: 2013-11-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibi...
    Medical condition: Adult kidney transplant recipients.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) SK (Completed) ES (Completed) PT (Completed) AT (Completed) NL (Completed) BE (Completed) GR (Completed) CZ (Completed) SI (Completed) BG (Completed) PL (Completed) HR (Completed) NO (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001128-38 Sponsor Protocol Number: pVAX/rhPSA -EP 2006 Start Date*: 2008-09-30
    Sponsor Name:Uppsala University Hospital
    Full Title: DNA Vaccine Coding for the Rhesus Prostate Specific Antigen (rhPSA) and Electroporation in Patients with Relapsed Prostate Cancer. A Phase I/II Study
    Medical condition: Patients with relapse of prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002465-28 Sponsor Protocol Number: ICANMINI Start Date*: 2016-02-19
    Sponsor Name:Klinikum der Universität München
    Full Title: Anti-donor alloreactivity-guided CNI minimization versus unguided standard triple therapy in living-donor kidney transplantation
    Medical condition: Renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015456-14 Sponsor Protocol Number: CAEB071A2214 Start Date*: 2010-01-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A partially blinded, prospective, randomized multicenter study evaluating efficacy, safety and tolerability of oral sotrastaurin plus standard or reduced exposure tacrolimus vs. myfortic plus tacro...
    Medical condition: Renal allograft transplantation
    Disease: Version SOC Term Classification Code Term Level
    12.0 10066543 Acute allograft rejection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) BE (Prematurely Ended) HU (Prematurely Ended) DE (Completed) SE (Prematurely Ended) NL (Prematurely Ended) DK (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001518-42 Sponsor Protocol Number: CERL080A2409 Start Date*: 2005-09-15
    Sponsor Name:Novartis Farmaceútica S.A
    Full Title: A six-month, prospective, multicenter, open label, parallel, randomized study of the safety, tolerability and efficacy of myfortic® (ERL080) with Simulect®, corticosteroids and two different levels...
    Medical condition: de novo renal transplant
    Disease: Version SOC Term Classification Code Term Level
    10023438
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004101-33 Sponsor Protocol Number: 0468E-102362 Start Date*: 2015-04-07
    Sponsor Name:Wyeth Korea, Inc.
    Full Title: A Clinical Study to Evaluate the Efficacy and Safety of Cyclosporine (CsA) and Sirolimus (SRL) Induction Followed by Cyclosporine Withdrawal in Korean Renal Allograft Recipients
    Medical condition: Renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    17.1 10042613 - Surgical and medical procedures 10038533 Renal transplant PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004154-28 Sponsor Protocol Number: TED16414 Start Date*: 2020-04-20
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Phase 1b/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of isatuximab (SAR650984) in patients awaiting kidney transplantation
    Medical condition: (Patients awaiting) kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021425 Immune system disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013917-91 Sponsor Protocol Number: AIC246-01-II-02 Start Date*: 2010-02-09
    Sponsor Name:AiCuris GmbH & Co. KG
    Full Title: A randomized, double-blind, placebo controlled trial to evaluate the safety, tolerability and antiviral activity of 12 weeks’ treatment with a new antiviral HCMV drug
    Medical condition: Prevention of active human cytomegalovirus (HCMV) replication by re-infection or re-activation in HCMV seropositive patients after human blood precursor cell (HBPC) transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000441-12 Sponsor Protocol Number: 0624-201 Start Date*: 2012-09-21
    Sponsor Name:VIROPHARMA Incorporated
    Full Title: A randomized, double-blind, placebo-controlled pilot study to evaluate the safety and effect of Cinryze (C1 Esterase Inhibitor (Human)) for the treatment of acute antibody-mediated rejection in rec...
    Medical condition: Acute Antibody Mediated Rejection (AMR) in kidney transplant patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10044439 Transplant rejection PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000662-38 Sponsor Protocol Number: D419NC00001 Start Date*: 2017-01-18
    Sponsor Name:MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors
    Medical condition: Advanced solid tumor
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) ES (Ongoing) FR (Ongoing) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004011-20 Sponsor Protocol Number: GS-US-380-1878 Start Date*: 2016-02-12
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004612-97 Sponsor Protocol Number: CEC-4/CEL Start Date*: 2021-08-12
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: A phase IIb, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet
    Medical condition: Treatment of celiac disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10007864 Celiac disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing) LT (Ongoing) DE (Ongoing) NO (Ongoing) EE (Ongoing) IE (Ongoing) AT (Ongoing) IT (Ongoing) SE (Ongoing) ES (Ongoing) PL (Ongoing) BG (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003949-42 Sponsor Protocol Number: 208471 Start Date*: 2019-12-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or i...
    Medical condition: Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-000641-33 Sponsor Protocol Number: PAX Start Date*: 2022-04-21
    Sponsor Name:Fundació FLS de Lluita contra la Sida, les Malalties Infeccioses i la Promoció de la Salut i La Ciència
    Full Title: Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study
    Medical condition: Post-Acute-Covid-19 Syndrome
    Disease: Version SOC Term Classification Code Term Level
    24.0 10021881 - Infections and infestations 10085503 Post-acute COVID-19 syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003166-12 Sponsor Protocol Number: FRAME-001 Start Date*: 2022-03-21
    Sponsor Name:Frame Pharmaceuticals B.V.
    Full Title: A Phase II Trial of Personalized Tumor Neoantigen Based Vaccine FRAME-001 for Advanced Non-Small Cell Lung Cancer
    Medical condition: Advanced Non- small cell lung carcinoma (NSCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002279-16 Sponsor Protocol Number: EOGBM1-18 Start Date*: 2020-01-02
    Sponsor Name:Enterome
    Full Title: A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIe...
    Medical condition: Progressive or recurrent Glioblastoma (PG)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004063-36 Sponsor Protocol Number: CELIM-RCD-002 Start Date*: 2016-02-22
    Sponsor Name:Celimmune LLC
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients with Type II Refractory Celiac Disease, an In Situ Sm...
    Medical condition: Type II Refractory Celiac Disease (RCD-II)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA